ReviewVascular health and risk management2007
Comprehensive cardiovascular risk management--what does it mean in practice?
Review in Vascular health and risk management, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Long-term Cardiovascular and All-Cause Mortality following Elective Infrarenal Repair of the Abdominal Aortic Aneurysm: A Systematic Review and Meta-analysis.Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists · 2026Pooled it
- A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile.International journal of clinical practice · 2008Trial
- Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study.Clinical drug investigation · 2008Trial
- A Summary of Cardiometabolic Disorders in the Maghreb: Insights from the 2025 Saclay Cardiometabolic Summit.Cardiology and therapy · 2026Review
- Determinants of Poor Glycemic Control in Type 2 Diabetes Patients With Coronary Artery Disease: A Case-Control Study.Health science reports · 2026Article
- Trends and disparities in mortality associated with peripheral artery disease and hyperlipidemia, 1999-2024.Scientific reports · 2025Article
- Evaluating Cardiovascular Risk Factors Among Healthcare Professionals in Iran.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Ten Americas: a systematic analysis of life expectancy disparities in the USA.Lancet (London, England) · 2024Article
- Hemorrhagic stroke and atherogenic markers - is there any relation?Journal of family medicine and primary care · 2024Article
- Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2019Observational
- Rethinking risk assessment for emerging technology first-in-human trials.Medicine, health care, and philosophy · 2016Article
- Mobile Phone-Based Lifestyle Intervention for Reducing Overall Cardiovascular Disease Risk in Guangzhou, China: A Pilot Study.International journal of environmental research and public health · 2015Article
- Estimation of the cardiovascular risk using World Health Organization/International Society of Hypertension (WHO/ISH) risk prediction charts in a rural population of South India.International journal of health policy and management · 2015Article
- Assessing the global burden of ischemic heart disease, part 2: analytic methods and estimates of the global epidemiology of ischemic heart disease in 2010.Global heart · 2012Article
- A Community-based Cross-sectional Study of Cardiovascular Risk in a Rural Community of Puducherry.Heart views : the official journal of the Gulf Heart AssociationArticle
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The continued movement away from the treatment of individual cardiovascular (CV) risk factors to managing overall and lifetime CV risk is likely to have a significant impact on slowing the rate of increase in cardiovascular disease (CVD). However, the management of CVD is currently far from optimal even in parts of the world with well-developed and well-funded healthcare systems. Effective implementation of the knowledge, treatment guidelines, diagnostic tools, therapeutic interventions, and management programs that exist for CVD continues to evade us. A thorough understanding of the multifactorial nature of CVD is essential to its effective management. Improvements continue to be made to management guidelines, risk assessment tools, treatments, and care programs pertaining to CVD. Ultimately, however, preventing the epidemic of CVD will require a combination of both medical and public health approaches. In addition to improvements in the "high-risk" strategy, which forms the basis of current CVD management, an increase in the utilization of population-based management strategies needs to be made to attempt to reduce the number of patients falling within the "at-risk" stratum for CVD. This review outlines how a comprehensive approach to CVD management might be achieved.
Indexed as
Identifiers
18078010PMC2291303What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.